Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Grants Accelerated Approval to Retifanlimab-dlwr for Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma

Evidence for efficacy is based on the results from the PODIUM-201 study
28 Mar 2023

On 22 March 2023, the US Food and Drug Administration (FDA) granted accelerated approval to retifanlimab-dlwr (Zynyz, Incyte Corporation) for adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).

Full prescribing information for Zynyz is available here.

Safety and efficacy were evaluated in PODIUM-201 (NCT03599713), an open-label, multiregional, single-arm study evaluating 65 patients with metastatic or recurrent locally advanced MCC who had not received prior systemic therapy for advanced disease.

The major efficacy outcome measures were objective response rate (ORR) and duration of response (DoR) assessed by an independent central review committee according to RECIST v1.1. The ORR was 52% (95% confidence interval 40, 65) with complete response rate of 18%. Twenty-six patients (76%) had a DoR ≥ 6 months and 21 (62%) had a DoR ≥ 12 months.

The safety population consisted of 105 patients with MCC. The most common (≥10%) adverse reactions were fatigue, musculoskeletal pain, pruritus, diarrhoea, rash, pyrexia, and nausea. Serious adverse reactions occurred in 22% of patients receiving retifanlimab-dlwr.

The recommended retifanlimab-dlwr dose is 500 mg administered as an intravenous infusion over 30 minutes every 4 weeks until disease progression, unacceptable toxicity, or up to 24 months.

This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment.

This application was granted priority review, fast track, and orphan drug designation.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System. 

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact FDA’s Oncology Center of Excellence Project Facilitate.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.